盘前公告 | 信达生物折让4.87%配售5200万股股份
uSMART盈立智投1月15日消息,周五港股盘前,信达生物发布《根据一般授权配售新股份》公告称,于2021年1月15日(交易时段前),本公司与联席配售代理订立配售协议,据此,本公司同意委任联席配售代理,及联席配售代理同意作为配售代理行事,以作为本公司的代理根据配售协议所载的条款并在其条件规限下,促使承配人(否则自行)以配售价购买52,000,000股配售股份。
配售事项所得款项总额预期约为47.27亿港元。
每股配售股份90.9港元,相当于:(i)股份于2021年1月14日(即配售协议日期前一天)在联交所所报的收市价每股95.55港元折让约4.87%;及(ii)股份于紧接配售协议日期前连续五个交易日在联交所所报的平均收市价每股89.23港元溢价约1.87%。
点击可跳转阅读《信达生物根据一般授权配售新股份》公告原文件PDF。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.